# South Korea Gene Editing Market > South Korea Gene Editing Market Research Report: Size, Share, Trend Analysis By Technology (CRISPR, TALEN, ZFN, Antisense, others), By Applications (Genetic Engineering, Gene Therapy, Cell Line Engineering, Others), By Method (Ex-vivo, In-vivo) and By End Users (Biotechnology and Pharmaceutical Companies, Contract Research Organizations (CROs), Academic and amp; Government Research Institutes) - Growth Outlook & Industry Forecast 2025 To 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 20.94% - **2024:** $ 173.8 Million - **2025:** $ 210.19 Million - **2035:** $ 1,407.34 Million - **Key Players:** CRISPR Therapeutics (CH), Editas Medicine (US), Intellia Therapeutics (US), Regeneron Pharmaceuticals (US), Sangamo Therapeutics (US), Vertex Pharmaceuticals (US), Amgen (US), Bayer (DE), Novartis (CH) **Report ID:** MRFR/LS/51137-HCR · **Pages:** 200 · **Author:** Rahul Gotadki · **Last Updated:** August 07, 2026 **URL:** https://www.marketresearchfuture.com/reports/south-korea-gene-editing-market-52898 --- ## Market Summary ## **South Korea Gene Editing Market Overview** As per MRFR analysis, the South Korea Gene Editing Market Size was estimated at 143.8 (USD Million) in 2023. The South Korea Gene Editing Market Industry is expected to grow from 173.4 (USD Million) in 2024 to 1,075 (USD Million) by 2035. The South Korea Gene Editing Market CAGR (growth rate) is expected to be around 18.041% during the forecast period (2025 - 2035). ### **Key South Korea Gene Editing Market Trends Highlighted** Advancements in biotechnology and increased investment from both the public and private sectors are driving significant growth in the South Korea Gene Editing Market. Innovation has been stimulated by the government's proactive approach to fostering research and development, with initiatives that concentrate on the establishment of a robust ecosystem in a robust biotechnology. The Ministry of Science and ICT, in collaboration with a variety of research institutions, is committed to the advancement of gene editing technologies, including CRISPR, with the objective of enhancing healthcare and agriculture. This not only emphasizes the government's dedication but also encourages collaboration between academia and industry, which is crucial for the development of effective gene therapies. Key sectors such as agriculture, healthcare, and environmental management are being prioritized as opportunities in the South Korean gene editing market are investigated. The utilization of gene editing for crop enhancement is becoming increasingly popular in South Korea as a means of addressing food security concerns, particularly in the context of climate change. In the same vein, gene editing technology is being employed to advance healthcare, particularly in the areas of personalized medicine and rare disease treatments. The social acceptance of genetically modified products is also on the rise, which enables the widespread application of these technologies. Local biotech firms are collaborating with global actors to improve their research capabilities and create innovative gene editing applications, as evidenced by recent trends. This has increased partnerships and collaborations within South Korea. Additionally, educational initiatives and awareness campaigns are being implemented to enhance the public's understanding of the safety and advantages of gene editing technologies. In general, these market trends are indicative of a dynamic landscape in South Korea that is dedicated to utilizing the potential of gene editing to resolve critical challenges in agriculture and health, thereby establishing the country as a key player in this evolving field. Source: Primary Research, Secondary Research, _Market Research Future_ Database**,****and Analyst Review** ## **South Korea Gene Editing Market Drivers** ### **Increasing Investment in Research and Development** The South Korea Gene Editing Market is experiencing substantial growth driven by heightened investment in Research and Development (R&D) activities. The South Korean government has pledged significant financial support to biotechnology, with a plan to invest approximately USD 1.1 billion in the biotechnology sector over the next five years. This initiative aims to enhance global competitiveness and innovation in gene editing technologies. Prominent universities and institutions, such as KAIST (Korea Advanced Institute of Science and Technology), are also increasing their focus on genome editing research. In recent years, KAIST reported a rise of over 50% in research publications related to CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) technologies, underscoring a robust academic interest and foundational advancement in this field. As research progresses and novel applications are discovered, the market is anticipated to flourish, further fueled by exciting breakthroughs related to genetic treatments and agricultural advancements. ### **Rising Incidence of Genetic Disorders** The rising incidence of genetic disorders in South Korea acts as a significant driver for the South Korea Gene Editing Market Industry. According to recent statistics from the Korean National Institute of Health, around 1 in 400 individuals in South Korea is affected by a genetic disorder, representing a growing need for effective therapies. Gene editing technologies, particularly CRISPR, are being explored as potential solutions to treat various genetic conditions such as muscular dystrophy and cystic fibrosis. The increasing awareness and demand for genetic therapies have prompted collaborations among major pharmaceutical firms and research institutions. Noteworthy organizations like Samsung Biologics are actively investing in gene editing solutions, as they recognize the implications of genetically engineered treatments on healthcare. This growing recognition and urgency to address genetic disorders encourage advancements in gene editing, thereby propelling market growth. ### **Expansion of Agricultural Applications** The South Korea Gene Editing Market is also significantly shaped by the expansion of agricultural applications of gene editing technology. With the global population projected to reach 10 billion by 2050, South Korea is prioritizing sustainable food production to meet future food demands. The government's recent policies aimed at promoting genetically modified organisms (GMOs) have facilitated research in gene editing for agricultural enhancements. Reports indicate that South Korea's agricultural productivity has the potential to increase by up to 30% through gene editing interventions, specifically in developing drought-resistant and pest-resistant crop varieties. Establishments like the Rural Development Administration (RDA) have been instrumental in pioneering research on gene editing technologies for crop improvement. Efforts are underway to integrate gene editing in South Korean farming practices, which is expected to accelerate the adoption of gene editing solutions, consequently invigorating the market. ### **Supportive Regulatory Environment** The supportive regulatory environment in South Korea significantly fosters the growth of the South Korea Gene Editing Market Industry. The Ministry of Food and Drug Safety has introduced regulatory frameworks that streamline the approval process for gene editing technologies, thereby reducing the time required for research and commercialization. For example, the newly implemented 'Genome Editing Guide' aims to provide clarity on regulatory requirements for gene editing projects, facilitating a smoother transition from lab to market. As safety assessments are efficiently conducted, the reliance on gene editing technologies in various sectors, such as healthcare and agriculture, grows. The leading biopharmaceutical firm, Hanmi Pharmaceutical, has hailed the regulatory advancements as instrumental in accelerating its pipeline of gene therapies. The supportive policies bolster investor confidence, leading to increased funding and collaborative efforts in gene editing research, thus significantly driving market growth. ## **South Korea Gene Editing Market Segment Insights** ### **Gene Editing Market Technology Insights** The Technology segment of the South Korea Gene Editing Market is a rapidly evolving area, with significant contributions to biotechnology and life sciences. Among the most notable technologies is CRISPR, which has revolutionized the field by providing a cost-effective and precise method for gene editing, drawing considerable interest from both academic and commercial sectors. Its broad applications, ranging from agriculture to medicine, highlight its importance in enhancing crop resilience and developing treatments for genetic disorders. TALEN technology also plays a crucial role, particularly in gene therapy applications where precise modifications are necessary. Its ability to target specific genetic sequences allows for tailored therapeutic solutions, making it a vital component in research aimed at addressing complex genetic diseases. ZFN, while slightly older in the market, continues to be influential due to its capability to create double-strand breaks at specified gene locations, facilitating gene disruption or correction. This technology sees significant utilization in agricultural biotechnology, where it is used to introduce desirable traits into crops. Antisense technology, which operates differently by using synthetic strands of nucleic acids to bind to and modulate gene expression, is noteworthy for its potential in treating various diseases, especially those linked to single-gene defects. This segment is gaining traction in South Korea, where national biotech initiatives have fostered research in genetic disorders and cancer treatment, offering new therapeutic avenues for patients. Additionally, the broader others’ category encompasses emerging technologies that aim to complement or improve existing methodologies, ensuring that South Korea remains at the forefront of gene editing innovation. The country’s supportive regulatory environment and government grants for Research and Development further enhance the landscape, positioning South Korea as a leader in global gene editing advancements. Overall, the Technology segment promises substantial growth, driven by ongoing innovations and applications across health, agriculture, and environmental sustainability, solidifying its pivotal role within the South Korea Gene Editing Market. Source: Primary Research, Secondary Research, _Market Research Future_ Database**,****and Analyst Review** ### **Gene Editing Market Application Insights** The South Korea Gene Editing Market, particularly within the Application segment, exhibits promising potential driven by advancements in technology and increased investments in Research and Development. Genetic Engineering stands out as an essential application, enabling the manipulation of DNA to achieve desired traits in organisms, which plays a crucial role in agriculture and pharmaceuticals. Gene Therapy, another pivotal area, focuses on correcting genetic disorders by introducing, removing, or altering genetic material within a patient’s cells, showcasing significant promise for treating inherited diseases and cancers. Cell Line Engineering is equally important as it provides frameworks for developing monoclonal antibodies and vaccines, crucial in biopharmaceutical production and research. Additional applications involving various techniques and processes cater to niche markets, enhancing the versatility of the South Korea Gene Editing Market. The rising prevalence of genetic disorders, coupled with an aging population and expanding biotechnological infrastructure, acts as a substantial driver for market growth. Despite challenges such as ethical considerations and regulatory hurdles, the opportunities within these applications are set to expand, reflecting the dynamic evolution of the South Korea Gene Editing Market. ### **Gene Editing Market Method Insights** The South Korea Gene Editing Market is witnessing substantial growth, particularly in the Method segment, which encompasses various approaches like Ex-vivo and In-vivo techniques. Ex-vivo gene editing allows for the modification of cells outside the body and has seen increased application in Research and Development for therapeutic purposes, making it significant in areas like cancer treatment and genetic disorders. Meanwhile, In-vivo gene editing involves direct modification within the living organism, which holds promise for genetic therapies and has been instrumental in advancements in agricultural biotechnology. The South Korean government has been actively supportive of gene editing initiatives, facilitating research and fostering collaboration between academic institutions and industry players. With a focus on innovative healthcare solutions and agricultural advancements, both Ex-vivo and In-vivo methods are driving factors in the South Korea Gene Editing Market, aligning with national priorities for improving public health and food security. As more discoveries emerge, these methods will play crucial roles in shaping the future landscape of gene editing technologies. ### **Gene Editing Market End User Insights** The end-user segment of the South Korea Gene Editing Market showcases a diverse landscape with significant contributions from various sectors. Biotechnology and Pharmaceutical Companies largely drive the market, focusing on developing genetic therapies and innovative treatments that address critical healthcare challenges. Contract Research Organizations (CROs) play a vital role as enablers, facilitating clinical trials and offering specialized research services that support the rapid advancement of gene editing technologies. Meanwhile, Academic and Government Research Institutes, with their strong emphasis on Research and Development, contribute to the foundational knowledge and groundbreaking discoveries needed for the evolution of gene editing applications. This segment benefits from South Korea's robust commitment to biotechnology, characterized by substantial government support for scientific research and development initiatives. The increasing prevalence of genetic disorders and the growing demand for personalized medicine further underscore the significance of this segment in addressing the health needs of the population. Additionally, advancements in CRISPR technology continue to fuel opportunities within this space, reflecting a strong momentum for growth and innovation across the end-user segment in South Korea's Gene Editing Market. ## **South Korea Gene Editing Market Key Players and Competitive Insights** The South Korea Gene Editing Market has witnessed significant advancements and competitive dynamics in recent years, driven by the rapid evolution of biotechnology and increasing investment in research and development. This burgeoning market reflects the nation's commitment to being at the forefront of genetic research, leveraging cutting-edge technologies such as CRISPR, genome sequencing, and synthetic biology. The competitive landscape is characterized by a blend of established industry leaders and innovative startups, all striving to carve out their unique niches. As companies enhance their capabilities and expand their product offerings, the market is expected to witness further consolidation and strategic collaborations that foster growth and innovation, bolstering South Korea's position as a key player in the global gene editing arena. Hana Genomics has emerged as a prominent entity in the South Korea Gene Editing Market, capitalizing on its strong research capabilities and a dedicated focus on genetic therapies. The company has cultivated strategic partnerships with academic institutions and research organizations, allowing it to tap into the latest scientific advancements in gene editing technologies. By concentrating on innovative solutions tailored to address genetic disorders, Hana Genomics has developed a reputation for excellence in delivering effective therapies that resonate with the healthcare community. The strengths of Hana Genomics lie in its pioneering approaches and ability to rapidly adapt to changes in consumer demands and scientific breakthroughs, solidifying its competitive edge and contributing to its expanding presence in the market. Samsung Biologics has positioned itself as a formidable player in the South Korea Gene Editing Market with a comprehensive portfolio of services, particularly in biologics and therapeutic development. With key products spanning a range of biologics-related offerings, the company maintains a strong footprint through its state-of-the-art manufacturing facilities, which profoundly enhance its capacity and efficiency. The synergy between Samsung Biologics and its parent company creates significant advantages in terms of resource allocation and technological expertise, leading to strategic mergers and acquisitions that bolster its market presence. By leveraging these strengths, the company is able to offer innovative solutions that align with the demands of biopharmaceutical partners, further establishing itself as a leader in gene editing advancements within the South Korean landscape. ### **Key Companies in the South Korea Gene Editing Market Include** - Hana Genomics - Samsung Biologics - Sillajen - Medipost - Genomictree - Toolgen - Celltrion - Eirgenix - Hugel - Seegene - NexGene - MediPost - Genexine - Korean Bioprocessing Institute ## **South Korea Gene Editing Market Industry Developments** The South Korea Gene Editing Market has seen significant developments recently, particularly with companies like Hana Genomics, Samsung Biologics, and Sillajen leading the way in Research and Development initiatives. In July 2023, Celltrion announced advancements in its gene therapy platforms, enhancing its position in the expanding gene editing landscape. Major companies such as Medipost and Genexine are also experiencing growth, contributing to the increase in market valuation, influenced by robust funding and government support for innovative biotechnologies. In September 2023, Eirgenix entered into a strategic partnership with Toolgen to advance research capabilities in gene editing technologies, reflecting a trend of collaboration in the sector. Over the past two to three years, the South Korean government has committed substantial resources to foster innovation in biotechnology, pushing the market's growth trajectory. Over the last year, Hugel and Seegene have expressed intentions to explore gene editing applications in personalized medicine, further positioning themselves within a competitive marketplace. Such endeavors signify an ongoing evolution in South Korea’s gene editing sector, aligning with national goals to enhance healthcare solutions and improve therapeutic outcomes. ## **South Korea Gene Editing Market Segmentation Insights** ### **Gene Editing Market Technology Outlook** - CRISPR - TALEN - ZFN - Antisense - others ### **Gene Editing Market Application Outlook** - Genetic Engineering - Gene Therapy - Cell Line Engineering - Others ### **Gene Editing Market Method Outlook** - Ex-vivo - In-vivo ### **Gene Editing Market End User Outlook** - Biotechnology and Pharmaceutical Companies - Contract Research Organizations (CROs) - Academic & Government Research Institutes ## Market Drivers ### Advancements in CRISPR Technology Recent advancements in CRISPR technology are significantly impacting the gene editing market in South Korea. This innovative gene editing tool has revolutionized the ability to modify DNA with unprecedented precision and efficiency. As researchers and companies continue to refine CRISPR techniques, the applications within the gene editing market are expanding rapidly. For instance, CRISPR is being utilized in agricultural biotechnology to develop crops that are resistant to pests and diseases, thereby enhancing food security. The market is expected to reach a valuation of $1 billion by 2027, driven by these technological advancements. ### Collaborative Research Initiatives Collaborative research initiatives among universities, research institutions, and private companies are fostering innovation within the gene editing market in South Korea. These partnerships are essential for sharing knowledge, resources, and expertise, which can lead to breakthroughs in gene editing technologies. For example, joint projects focusing on gene therapies for rare diseases are gaining traction, with funding from both government and private sectors. Such collaborations not only enhance the research capabilities but also accelerate the commercialization of gene editing solutions, thereby strengthening the gene editing market. ### Rising Investment in Biotechnology The gene editing market in South Korea is experiencing a surge in investment, particularly from both public and private sectors. The South Korean government has allocated substantial funding, amounting to approximately $500 million, to support biotechnology research and development. This financial backing is aimed at fostering innovation in gene editing technologies, which are crucial for advancements in healthcare and agriculture. Furthermore, private companies are increasingly investing in gene editing startups, indicating a growing confidence in the market's potential. This influx of capital is likely to accelerate the development of new gene editing applications, thereby enhancing the overall growth of the gene editing market. ### Growing Public Awareness and Acceptance Public awareness and acceptance of gene editing technologies are on the rise in South Korea, contributing positively to the gene editing market. Educational campaigns and media coverage have played a crucial role in informing the public about the benefits and potential of gene editing. As citizens become more informed, there is a growing willingness to embrace gene editing solutions, particularly in healthcare and agriculture. This shift in public perception is likely to facilitate regulatory approvals and encourage investment in gene editing projects, further propelling the market's growth. ### Increasing Demand for Precision Medicine The gene editing market is witnessing a notable shift towards precision medicine, driven by the rising demand for personalized healthcare solutions. In South Korea, the prevalence of genetic disorders and chronic diseases has prompted healthcare providers to seek innovative treatments that are tailored to individual genetic profiles. The gene editing market is positioned to meet this demand by offering advanced therapies that can modify genes to treat or prevent diseases. As a result, the market is projected to grow at a CAGR of 15% over the next five years, reflecting the increasing adoption of gene editing technologies in clinical settings. ## Future Outlook The [Gene Editing Market](https://www.marketresearchfuture.com/reports/gene-editing-market-707) in South Korea is projected to grow at a 20.94% CAGR from 2025 to 2035, driven by advancements in biotechnology, regulatory support, and increasing applications in agriculture and healthcare. **New opportunities:** - Development of CRISPR-based therapeutics for rare genetic disorders. - Investment in precision agriculture technologies utilizing gene editing. - Partnerships with biotech firms for innovative gene editing solutions. By 2035, the gene editing market is expected to be robust, driven by innovation and strategic collaborations. ## Segment Insights ### By Technology: CRISPR (Largest) vs. TALEN (Fastest-Growing) In the South Korea gene editing market, CRISPR technology dominates the landscape with a significant share, driven by its versatility and efficiency in genetic modifications. TALEN follows closely, gaining traction due to its precision and ability to target specific DNA sequences, making it a preferred choice for emerging applications. Both technologies are witnessing interest from research institutions and biotechnology firms, contributing to their overall market performance. Recent growth trends indicate a surge in investments and advancements in gene editing technologies, particularly in CRISPR and TALEN. The rapid development of gene therapies and agricultural biotechnology is propelling their adoption, especially as regulatory frameworks become more favorable. Furthermore, increased funding and collaboration among research entities are expected to continue driving these technologies, with TALEN poised to become a key player in the coming years. Technology: CRISPR (Dominant) vs. TALEN (Emerging) CRISPR, as the dominant technology in the South Korea gene editing market, is characterized by its ease of use and cost-effectiveness, which has led to widespread applications in both academic and industrial settings. It is particularly favored for its ability to make precise edits with minimal off-target effects, thus revolutionizing genetic research and therapeutic development. On the other hand, TALEN is emerging as a strong contender due to its high specificity and versatility, enabling researchers to develop customized gene modifications for specific applications. As stakeholders increasingly recognize TALEN's potential, its growth is accelerated by technological advancements and rising demand for precise genetic interventions. ### By Application: Genetic Engineering (Largest) vs. Clinical Application (Fastest-Growing) In the South Korea gene editing market, genetic engineering represents the largest segment, commanding a significant share due to its applications across various fields including agriculture, pharmaceuticals, and biotechnology. The clinical application segment, while not as large, is rapidly gaining ground as advancements in gene therapy and personalized medicine emerge, appealing to a growing patient base seeking innovative treatment solutions. Growth trends in this market are being driven by increasing investments in research and development, as well as a rising demand for advanced therapeutic solutions. The adoption of CRISPR technology and other novel gene-editing tools are enhancing the capabilities within clinical applications, highlighting the potential for transformative treatments. Additionally, regulatory support and public awareness of genetic therapies are likely to propel the market further, especially within the clinical segment. Genetic Engineering (Dominant) vs. Clinical Application (Emerging) Genetic engineering remains the dominant segment in the South Korea gene editing market, characterized by its extensive use in modifying organisms for enhanced traits or treatment of diseases. This segment benefits from established technologies and a robust infrastructure supporting its applications in therapeutics and agriculture. On the other hand, clinical application, labeled as emerging, is witnessing rapid advancements, particularly with gene therapies that target genetic disorders and cancers. This segment is characterized by innovative approaches, driven by collaborations between academia and biotech firms, leading to the development of groundbreaking treatments that are tailored to individual genetic profiles. As both segments evolve, they are anticipated to complement each other, fostering a holistic approach to genetic modification and therapy. ### By Method: Ex-vivo (Largest) vs. In-Vivo (Fastest-Growing) In the South Korea gene editing market, the distribution of market share among methods indicates that the Ex-vivo segment holds a significant portion of the market, showcasing advanced capabilities in precision editing and targeted applications. This method allows for precise modifications outside the body, making it favorable for therapeutic developments and enabling tailored treatment options. On the other hand, the In-Vivo method is gaining traction, characterized by its ability to administer gene editing directly within the organism, offering higher efficiency in certain applications and expanding the potential for therapeutic breakthroughs. The growth trends in this segment reflect a rising demand for innovative therapies and increased funding for research and development in gene editing techniques. The Ex-vivo method is positioned as a dominant player due to its established track record in clinical applications, while the In-Vivo method is emerging rapidly, driven by advancements in delivery mechanisms and growing interest in gene therapies for genetic disorders. Factors such as regulatory support and rising healthcare expenditures are further propelling the innovations in both methods, paving the way for significant progress in the South Korea gene editing market. Method: Ex-vivo (Dominant) vs. In-Vivo (Emerging) The Ex-vivo method is characterized by its meticulous approach, allowing researchers to edit genes in a controlled environment before reintroducing the modified cells back into the patient. This method provides a greater degree of accuracy and safety, making it particularly suitable for applications in therapeutic settings, especially in oncology and genetic diseases. On the other hand, the In-Vivo method is gaining prominence as an emerging technique that enables direct editing within a living organism. This method's appeal lies in its potential for rapid implementation and the ability to address disorders at the cellular level without the need for extensive exogenous manipulation. As innovations enhance delivery techniques, the In-Vivo segment is quickly evolving, driven by its promise for broader applications and effective treatments in the South Korea gene editing market. ### By End User: Biotechnology and Pharmaceutical Companies (Largest) vs. Contract Research Organizations (Fastest-Growing) In the South Korea gene editing market, biotechnology and pharmaceutical companies hold the largest share, capitalizing on advancements in genetic research and therapeutic applications. This segment benefits from significant investments in R&D, enabling these companies to develop innovative products that meet the increasing demand for gene therapies and personalized medicine. This dominance is supported by strong collaborations with academic institutions and government entities. On the other hand, contract research organizations (CROs) are emerging as the fastest-growing segment in the market. The surge in outsourcing research and development activities to CROs is driven by the need for specialized expertise and cost-effectiveness. Additionally, the growing trend towards precision medicine is propelling demand for CRO services that can conduct tailored clinical trials and regulatory support, thereby enhancing their market trajectory. Biotechnology and Pharmaceutical Companies (Dominant) vs. Contract Research Organizations (Emerging) Biotechnology and pharmaceutical companies represent the dominant players in the South Korea gene editing market, characterized by their robust infrastructure, substantial financial resources, and comprehensive knowledge in molecular biology. These companies are heavily involved in the development of gene-based therapies for various genetic disorders, gaining traction through innovative solutions and strategic partnerships. In contrast, contract research organizations (CROs) are positioned as the emerging segment, providing essential services that support the research initiatives of biotech and pharmaceutical firms. They are increasingly being relied upon for their specialized expertise in clinical trials and regulatory compliance, allowing for accelerated development timelines and reduced costs. This symbiotic relationship is critical as both segments work together to navigate the complexities of the gene editing landscape. ## Competitive Benchmarking The [gene editing market](https://www.marketresearchfuture.com/reports/gene-editing-market-707) in South Korea is characterized by a dynamic competitive landscape, driven by rapid technological advancements and increasing investments in research and development. Key players such as CRISPR Therapeutics (CH), Editas Medicine (US), and Intellia Therapeutics (US) are at the forefront, focusing on innovative solutions to address genetic disorders. These companies are strategically positioned to leverage their proprietary technologies, with an emphasis on partnerships and collaborations that enhance their operational capabilities. The collective strategies of these firms contribute to a competitive environment that is increasingly focused on innovation and the development of cutting-edge therapies. In terms of business tactics, companies are increasingly localizing manufacturing and optimizing supply chains to enhance efficiency and reduce costs. The market structure appears moderately fragmented, with several players vying for market share. However, the influence of major companies is substantial, as they set the pace for technological advancements and regulatory compliance, thereby shaping the overall market dynamics. In October 2025, CRISPR Therapeutics (CH) announced a strategic partnership with a leading South Korean biotech firm to accelerate the development of CRISPR-based therapies. This collaboration is expected to enhance CRISPR's access to local expertise and resources, potentially expediting the commercialization of innovative treatments in the region. Such partnerships are indicative of a broader trend where companies seek to leverage local knowledge to navigate regulatory landscapes more effectively. In September 2025, Editas Medicine (US) launched a new initiative aimed at expanding its research capabilities in South Korea, focusing on gene editing applications for rare diseases. This move underscores the company's commitment to tapping into the growing South Korean market, which is increasingly recognized for its robust healthcare infrastructure and supportive regulatory environment. By establishing a stronger presence, Editas aims to enhance its competitive edge and foster innovation in gene therapies. In August 2025, Intellia Therapeutics (US) reported a significant milestone in its clinical trials for a novel gene editing treatment, demonstrating promising results in early-stage patients. This development not only reinforces Intellia's position as a leader in the field but also highlights the importance of clinical validation in gaining market trust. The successful outcomes of such trials are likely to influence investor confidence and drive further investment into gene editing technologies. As of November 2025, current trends in the gene editing market include a pronounced shift towards digitalization and the integration of artificial intelligence in research and development processes. Strategic alliances are becoming increasingly vital, as companies recognize the need for collaboration to enhance innovation and expedite product development. Looking ahead, competitive differentiation is expected to evolve, with a greater emphasis on technological advancements and supply chain reliability rather than solely on price. This shift suggests that companies that prioritize innovation and strategic partnerships will likely emerge as leaders in the gene editing landscape. ## Recent News & Developments The South Korea Gene Editing Market has seen significant developments recently, particularly with companies like Hana Genomics, Samsung Biologics, and Sillajen leading the way in Research and Development initiatives. In July 2023, Celltrion announced advancements in its gene therapy platforms, enhancing its position in the expanding gene editing landscape. Major companies such as Medipost and Genexine are also experiencing growth, contributing to the increase in market valuation, influenced by robust funding and government support for innovative biotechnologies. In September 2023, Eirgenix entered into a strategic partnership with Toolgen to advance research capabilities in gene editing technologies, reflecting a trend of collaboration in the sector. Over the past two to three years, the South Korean government has committed substantial resources to foster innovation in biotechnology, pushing the market's growth trajectory. Over the last year, Hugel and Seegene have expressed intentions to explore gene editing applications in personalized medicine, further positioning themselves within a competitive marketplace. Such endeavors signify an ongoing evolution in South Korea’s gene editing sector, aligning with national goals to enhance healthcare solutions and improve therapeutic outcomes. ## Report Scope | MARKET SIZE 2024 | 173.8(USD Million) | | --- | --- | | MARKET SIZE 2025 | 210.19(USD Million) | | MARKET SIZE 2035 | 1407.34(USD Million) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 20.94% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Million | | Key Companies Profiled | CRISPR Therapeutics (CH), Editas Medicine (US), Intellia Therapeutics (US), Regeneron Pharmaceuticals (US), Sangamo Therapeutics (US), Vertex Pharmaceuticals (US), Amgen (US), Bayer (DE), Novartis (CH) | | Segments Covered | Technology, Application, Method, End User | | Key Market Opportunities | Advancements in gene editing technologies drive innovation in agriculture and healthcare sectors. | | Key Market Dynamics | Regulatory advancements and technological innovations drive growth in South Korea's gene editing market. | | Countries Covered | South Korea | ## Frequently Asked Questions **Q: What was the market valuation of the South Korea gene editing market in 2024?** A: The market valuation was $173.8 Million in 2024. **Q: What is the projected market valuation for the South Korea gene editing market by 2035?** A: The projected valuation for 2035 is $1407.34 Million. **Q: What is the expected CAGR for the South Korea gene editing market during the forecast period 2025 - 2035?** A: The expected CAGR is 20.94% during the forecast period 2025 - 2035. **Q: Which technology segment had the highest valuation in 2024?** A: The CRISPR technology segment had the highest valuation at $69.14 Million in 2024. **Q: What are the key applications driving the South Korea gene editing market?** A: Key applications include genetic engineering, valued at $69.52 Million, and clinical applications, valued at $104.28 Million in 2024. **Q: What methods are utilized in the South Korea gene editing market?** A: The Ex-vivo method was valued at $69.14 Million, while the In-Vivo method reached $104.66 Million in 2024. **Q: Who are the major end users in the South Korea gene editing market?** A: Major end users include biotechnology and pharmaceutical companies, valued at $69.52 Million, and contract research organizations (CROs), valued at $52.14 Million in 2024. **Q: Which companies are considered key players in the South Korea gene editing market?** A: Key players include CRISPR Therapeutics, Editas Medicine, Intellia Therapeutics, and Regeneron Pharmaceuticals. **Q: What was the valuation of the TALEN technology segment in 2024?** A: The TALEN technology segment was valued at $34.57 Million in 2024. **Q: How does the market for gene editing in South Korea compare to other regions?** A: While specific comparisons are not provided, the South Korea gene editing market is expected to grow significantly, indicating a robust development trajectory. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/south-korea-gene-editing-market-52898*